DK2614058T3 - Polymorfer og salte af n-[5-[4-(5-{[(2r,6s)-2,6-dimethyl-4-morpholinyl]methyl}-1,3-oxazol-2-yl)-1h-indazol-6-yl]-2-(methyloxy)-3-pyridinyl]methansulfonamid. - Google Patents
Polymorfer og salte af n-[5-[4-(5-{[(2r,6s)-2,6-dimethyl-4-morpholinyl]methyl}-1,3-oxazol-2-yl)-1h-indazol-6-yl]-2-(methyloxy)-3-pyridinyl]methansulfonamid. Download PDFInfo
- Publication number
- DK2614058T3 DK2614058T3 DK11755311.5T DK11755311T DK2614058T3 DK 2614058 T3 DK2614058 T3 DK 2614058T3 DK 11755311 T DK11755311 T DK 11755311T DK 2614058 T3 DK2614058 T3 DK 2614058T3
- Authority
- DK
- Denmark
- Prior art keywords
- salt
- polymorph
- methyl
- dimethyl
- added
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (14)
1. Polymorf (Form II) af /V-[5-[4-(5-{[(2Æ,6S)-2,6-dimethyl-4-nnorpholinyl]nnethyl}- 1.3- oxazol-2-yl)-l/-/-indazol-6-yl]-2-(methyloxy)-3-pyridinyl]methansulfonamid, kendet egnet ved, at den tilvejebringer et XRPD-mønster omfattende en top (°2Θ) ved 9,2 ± 0,1.
2. Polymorf ifølge krav 1, kendetegnet ved, at den tilvejebringer et XRPD-mønster omfattende toppe i alt væsentligt som angivet i tabel 1 Tabel 1
3. Polymorf ifølge krav 1 eller krav 2 i at den tilvejebringer et XRPD-mønster i alt væsentligt ifølge figur 1.
4. Polymorf (Form III) af /V-[5-[4-(5-{[(2R,6S)-2,6-dimethyl-4-morpholinyl]methyl)·- 1.3- oxazol-2-yl)-lH-indazol-6-yl]-2-(methyloxy)-3-pyridinyl]methansulfonamid, k e n d e t egnet ved, at den tilvejebringer et XRPD-mønster omfattende en top (°2Θ) ved 6,7 ± 0,1.
5. Polymorf ifølge krav 5, kendetegnet ved, at den tilvejebringer et XRPD-mønster omfattende toppe i alt væsentligt som angivet i tabel 2 Tabel 2
6. Polymorf ifølge krav 4 eller krav 5, kendetegnet ved, at den tilvejebringer et XRPD-mønster i alt væsentligt ifølge figur 2.
7. Polymorf (Form IV) af /V-[5-[4-(5-{[(2R,6S)-2,6-dimethyl-4-morpholinyl]methyl>- l,3-oxazol-2-yl)-lH-indazol-6-yl]-2-(methyloxy)-3-pyridinyl]methansulfonamid, kendet egnet ved, at den tilvejebringer et XRPD-mønster omfattende en top (°2Θ) ved omkring 5,8.
8. Polymorf ifølge krav 7, kendetegnet ved, at den tilvejebringer et XRPD-mønster omfattende toppe i alt væsentligt som angivet i tabel 3 Tabel 3
9. Polymorf ifølge krav 7 eller krav 8, kendetegnet ved, at den tilvejebringer et XRPD-mønster i alt væsentligt ifølge figur 3.
10. Salt af /V-[5-[4-(5-{[(2/?,6S)-2,6-dimethyl-4-morpholinyl]methyl>-l,3-oxazol-2-yl)-lH-indazol-6-yl]-2-(methyloxy)-3-pyridinyl]methansulfonamid som er natrium-, tosy-lat-, maleat-, hemipamoat-, heminaphthalendisulfonat-, mesitylensulfonat-, hemibiphenyl-disulfonat-, 2-naphthalensulfonat- (napsylat-), hemicinnamat-, hemisebacat-, hemipyro-mellitat- eller hemibenzendiacrylatsaltet.
11. Farmaceutisk sammensætning omfattende en polymorf eller et salt, som defineret i et hvilket som helst af krav 1 til 10 og én eller flere farmaceutisk acceptable excipien-ser.
12. Polymorf eller salt, som defineret i et hvilket som helst af krav 1 til 10 til anvendelse i medicinsk terapi.
13. Polymorf eller salt, som defineret i et hvilket som helst af krav 1 til 10 til anvendelse i behandling af en lidelse medieret af uhensigtsmæssig PI3-kinaseaktivitet.
14. Anvendelse af en polymorf eller et salt, som defineret i et hvilket som helst af krav 1 til 10 til fremstilling af et lægemiddel til anvendelse i behandling af en lidelse medieret af uhensigtsmæssig PI3-kinaseaktivitet.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38074810P | 2010-09-08 | 2010-09-08 | |
| PCT/EP2011/065419 WO2012032067A1 (en) | 2010-09-08 | 2011-09-06 | Polymorphs and salts of n- [5- [4- (5- { [(2r,6s) -2, 6 - dimethyl - 4 -morpholinyl] methyl} - 1, 3 - oxazol - 2 - yl) - 1h- inda zol-6-yl] -2- (methyloxy) - 3 - pyridinyl] methanesulfonamide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2614058T3 true DK2614058T3 (da) | 2015-09-28 |
Family
ID=44645691
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11755311.5T DK2614058T3 (da) | 2010-09-08 | 2011-09-06 | Polymorfer og salte af n-[5-[4-(5-{[(2r,6s)-2,6-dimethyl-4-morpholinyl]methyl}-1,3-oxazol-2-yl)-1h-indazol-6-yl]-2-(methyloxy)-3-pyridinyl]methansulfonamid. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8735390B2 (da) |
| EP (1) | EP2614058B1 (da) |
| JP (1) | JP5965402B2 (da) |
| DK (1) | DK2614058T3 (da) |
| ES (1) | ES2548036T3 (da) |
| HR (1) | HRP20151017T1 (da) |
| HU (1) | HUE026059T2 (da) |
| PL (1) | PL2614058T3 (da) |
| PT (1) | PT2614058E (da) |
| RS (1) | RS54286B1 (da) |
| SI (1) | SI2614058T1 (da) |
| SM (1) | SMT201500223B (da) |
| WO (1) | WO2012032067A1 (da) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2526966T3 (es) | 2008-06-05 | 2015-01-19 | Glaxo Group Limited | Compuestos novedosos |
| EP2280959B1 (en) | 2008-06-05 | 2012-04-04 | Glaxo Group Limited | 4-amino-indazoles |
| US8658635B2 (en) | 2008-06-05 | 2014-02-25 | Glaxosmithkline Intellectual Property Development Limited | Benzpyrazol derivatives as inhibitors of PI3 kinases |
| WO2010102958A1 (en) | 2009-03-09 | 2010-09-16 | Glaxo Group Limited | 4-oxadiazol-2 -yl- indazoles as inhibitors of p13 kinases |
| PL2899191T3 (pl) | 2009-04-30 | 2018-01-31 | Glaxo Group Ltd | Indazole podstawione oksazolem jako inhibitory kinazy PI3 |
| ES2602972T3 (es) * | 2010-09-08 | 2017-02-23 | Glaxosmithkline Intellectual Property Development Limited | Derivados de indazol para su uso en el tratamiento de infección por virus de la gripe |
| US9102668B2 (en) * | 2010-09-08 | 2015-08-11 | Glaxo Group Limited | Polymorphs and salts |
| GB201018124D0 (en) | 2010-10-27 | 2010-12-08 | Glaxo Group Ltd | Polymorphs and salts |
| JP6063870B2 (ja) | 2010-11-08 | 2017-01-18 | ライセラ・コーポレイション | ＲＯＲγ活性の阻害用のＮ−スルホニル化テトラヒドロキノリンおよび関連二環化合物および病気の治療 |
| WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
| AU2013259624B2 (en) | 2012-05-08 | 2017-10-19 | Lycera Corporation | Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease |
| EP2846804B1 (en) | 2012-05-08 | 2017-11-29 | Merck Sharp & Dohme Corp. | TETRAHYDRONAPHTHYRIDINE AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE |
| WO2014007951A2 (en) | 2012-06-13 | 2014-01-09 | Incyte Corporation | Substituted tricyclic compounds as fgfr inhibitors |
| WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
| KR20210010958A (ko) | 2012-11-08 | 2021-01-28 | 리젠 파마슈티컬스 소시에떼 아노님 | Pde4 억제제 및 pi3 델타 또는 이중 pi3 델타-감마 키나아제 억제제를 함유하는 약제학적 조성물 |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| DK2986610T5 (da) | 2013-04-19 | 2018-12-10 | Incyte Holdings Corp | Bicykliske heterocykler som fgfr-inhibitorer |
| JP6441910B2 (ja) | 2013-09-30 | 2018-12-19 | シャンハイ インリ ファーマシューティカル カンパニー リミティド | 縮合ピリミジン化合物、中間体、その調製方法、組成物及び使用 |
| EP3059238B1 (en) | 2013-10-16 | 2020-05-27 | Shanghai Yingli Pharmaceutical Co. Ltd. | Fused heterocyclic compound, preparation method therefor, pharmaceutical composition, and uses thereof |
| CA2923995A1 (en) | 2013-10-17 | 2015-04-23 | Glaxosmithkline Intellectual Property Development Limited | Pi3k inhibitor for treatment of respiratory disease |
| WO2015055691A1 (en) | 2013-10-17 | 2015-04-23 | Glaxosmithkline Intellectual Property Development Limited | Pi3k inhibitor for treatment of respiratory disease |
| WO2015095792A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Carbamate benzoxaxine propionic acids and acid derivatives for modulation of rorgamma activity and the treatment of disease |
| WO2015095795A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | TETRAHYDRONAPHTHYRIDINE, BENZOXAZINE, AZA-BENZOXAZINE, AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE |
| US9663502B2 (en) | 2013-12-20 | 2017-05-30 | Lycera Corporation | 2-Acylamidomethyl and sulfonylamidomethyl benzoxazine carbamates for inhibition of RORgamma activity and the treatment of disease |
| MX2016010998A (es) | 2014-02-27 | 2017-03-31 | Lycera Corp | Terapia celular adoptiva que usa un agonista de receptor huérfano gamma relacionado con receptor de ácido retinoico y métodos terapéuticos relacionados. |
| WO2015171558A2 (en) | 2014-05-05 | 2015-11-12 | Lycera Corporation | BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE |
| EP3140291A4 (en) | 2014-05-05 | 2018-01-10 | Lycera Corporation | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| EP3256450B1 (en) | 2015-02-11 | 2020-12-02 | Merck Sharp & Dohme Corp. | Substituted pyrazole compounds as ror-gamma-t inhibitors and uses thereof |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| NZ773116A (en) | 2015-02-20 | 2024-05-31 | Incyte Holdings Corp | Bicyclic heterocycles as fgfr inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| EP3292119A4 (en) | 2015-05-05 | 2018-10-03 | Lycera Corporation | DIHYDRO-2H-BENZO[b][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE |
| GB201509492D0 (en) * | 2015-06-02 | 2015-07-15 | Glaxosmithkline Ip Dev Ltd | Novel processes |
| US10611740B2 (en) | 2015-06-11 | 2020-04-07 | Lycera Corporation | Aryl dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease |
| AU2016344111A1 (en) | 2015-10-27 | 2018-05-10 | Merck Sharp & Dohme Corp. | Substituted bicyclic pyrazole compounds as RORgammaT inhibitors and uses thereof |
| CA3002853A1 (en) | 2015-10-27 | 2017-05-04 | Merck Sharp & Dohme Corp. | Heteroaryl substituted benzoic acids as rorgammat inhibitors and uses thereof |
| JP2018535958A (ja) | 2015-10-27 | 2018-12-06 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | ＲＯＲγＴ阻害薬としての置換インダゾール化合物及びその使用 |
| TWI820984B (zh) * | 2017-01-31 | 2023-11-01 | 美商基利科學股份有限公司 | 替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型 |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| SG11202010636VA (en) | 2018-05-04 | 2020-11-27 | Incyte Corp | Solid forms of an fgfr inhibitor and processes for preparing the same |
| BR112020022373A2 (pt) | 2018-05-04 | 2021-02-02 | Incyte Corporation | sais de um inibidor de fgfr |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| BR112022007163A2 (pt) | 2019-10-14 | 2022-08-23 | Incyte Corp | Heterociclos bicíclicos como inibidores de fgfr |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| JP2023505258A (ja) | 2019-12-04 | 2023-02-08 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤としての三環式複素環 |
| US11407750B2 (en) | 2019-12-04 | 2022-08-09 | Incyte Corporation | Derivatives of an FGFR inhibitor |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2022221170A1 (en) | 2021-04-12 | 2022-10-20 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
| EP4352059A1 (en) | 2021-06-09 | 2024-04-17 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9127376D0 (en) | 1991-12-24 | 1992-02-19 | Wellcome Found | Amidino derivatives |
| HU225869B1 (en) | 1992-04-02 | 2007-11-28 | Smithkline Beecham Corp | Compounds with antiallergic and antiinflammatory activity and pharmaceutical compns. contg. them |
| US5889056A (en) | 1994-06-15 | 1999-03-30 | Glaxo Wellsome Inc. | Enzyme inhibitors |
| EE03997B1 (et) | 1995-04-14 | 2003-04-15 | Glaxo Wellcome Inc. | Albuterooli doseeriv inhalaator |
| MY117948A (en) | 1997-01-13 | 2004-08-30 | Glaxo Group Ltd | Nitride oxide synthase inhibitors. |
| DE19723722A1 (de) | 1997-05-30 | 1998-12-10 | Schering Ag | Nichtsteroidale Gestagene |
| TW533865U (en) | 1997-06-10 | 2003-05-21 | Glaxo Group Ltd | Dispenser for dispensing medicament and actuation indicating device |
| WO1999016766A1 (fr) | 1997-10-01 | 1999-04-08 | Kyowa Hakko Kogyo Co., Ltd. | Derives de benzodioxole |
| US6506766B1 (en) | 1998-02-13 | 2003-01-14 | Abbott Laboratories | Glucocortiocoid-selective antinflammatory agents |
| ATE270278T1 (de) | 1998-03-14 | 2004-07-15 | Altana Pharma Ag | Phthalazinone pde iii/iv hemmer |
| GB9811599D0 (en) | 1998-05-30 | 1998-07-29 | Glaxo Group Ltd | Nitric oxide synthase inhibitors |
| US6352152B1 (en) | 1998-12-18 | 2002-03-05 | Smithkline Beecham Corporation | Method and package for storing a pressurized container containing a drug |
| US6119853A (en) | 1998-12-18 | 2000-09-19 | Glaxo Wellcome Inc. | Method and package for storing a pressurized container containing a drug |
| US6390291B1 (en) | 1998-12-18 | 2002-05-21 | Smithkline Beecham Corporation | Method and package for storing a pressurized container containing a drug |
| US6315112B1 (en) | 1998-12-18 | 2001-11-13 | Smithkline Beecham Corporation | Method and package for storing a pressurized container containing a drug |
| EP1175422A2 (en) | 1999-05-04 | 2002-01-30 | Ligand Pharmaceuticals Incorporated | Tetracyclic progesterone receptor modulator compounds and methods |
| ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| CO5180649A1 (es) | 1999-09-01 | 2002-07-30 | Abbott Lab | Antagonistas de los receptores de los glucocorticoides para el tratamiento de la diabetes para el tratamiento de la diabetes |
| OA11558A (en) | 1999-12-08 | 2004-06-03 | Advanced Medicine Inc | Beta 2-adrenergic receptor agonists. |
| PT2348032E (pt) | 2000-08-05 | 2015-10-14 | Glaxo Group Ltd | Éster s-fluorometílico do ácido 6.alfa.,9.alfa.-difluoro- 17.alfa.-'(2-furanilcarboxil)oxi]-11.beta.-hidroxi-16.alfa.- metil-3-oxo-androsta-1,4-dieno-17-carbotióico como um agente anti-inflamatório |
| CN1678594A (zh) | 2000-09-29 | 2005-10-05 | 葛兰素集团有限公司 | 用于治疗炎性疾病的吗啉－乙酰胺衍生物 |
| GB0031179D0 (en) | 2000-12-21 | 2001-01-31 | Glaxo Group Ltd | Nitric oxide synthase inhibitors |
| US6484903B2 (en) | 2001-01-09 | 2002-11-26 | Riverwood International Corporation | Carton with an improved dispensing feature in combination with a unique handle |
| GB0103630D0 (en) | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds |
| JP2004526720A (ja) | 2001-03-08 | 2004-09-02 | グラクソ グループ リミテッド | βアドレナリン受容体のアゴニスト |
| ES2296923T3 (es) | 2001-03-22 | 2008-05-01 | Glaxo Group Limited | Derivados formanilidas como agonistas del adrenorreceptor beta2. |
| CA2445839A1 (en) | 2001-04-30 | 2002-11-07 | Glaxo Group Limited | Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha |
| WO2002100879A1 (en) | 2001-06-12 | 2002-12-19 | Glaxo Group Limited | Novel anti-inflammatory 17.alpha.-heterocyclic-esters of 17.beta.carbothioate androstane derivatives |
| HU228508B1 (en) | 2001-09-14 | 2013-03-28 | Glaxo Group Ltd | Phenethanolamine derivatives and pharmaceutical composition containing them |
| WO2003042160A1 (en) | 2001-11-13 | 2003-05-22 | Theravance, Inc. | Aryl aniline beta-2 adrenergic receptor agonists |
| CA2472746A1 (en) | 2002-01-14 | 2003-07-24 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical formulations containing them and uses thereof |
| EP1467730A4 (en) | 2002-01-22 | 2010-03-10 | Univ California | Non-steroid ligands for the glucocorticoid receptor, compositions and uses thereof |
| GB0204719D0 (en) | 2002-02-28 | 2002-04-17 | Glaxo Group Ltd | Medicinal compounds |
| ES2298508T3 (es) | 2002-03-26 | 2008-05-16 | Boehringer Ingelheim Pharmaceuticals Inc. | Mimeticos de glucocorticoides, metodos para prepararlos, composiciones farmaceuticas y sus usos. |
| EP1490317A1 (en) | 2002-03-26 | 2004-12-29 | Boehringer Ingelheim Pharmaceuticals Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| DE10215316C1 (de) | 2002-04-02 | 2003-12-18 | Schering Ag | Chinolin- und Isochinolin-Derivate, ein pharmazeutisches Mittel und ihre Verwendung als Entzündungshemmer |
| AU2003221706B2 (en) | 2002-04-11 | 2008-02-28 | Merck Sharp & Dohme Corp. | 1H-Benzo[F]indazol-5-YL derivatives as selective glucocorticoid receptor modulators |
| DE60318193T2 (de) | 2002-04-25 | 2008-12-04 | Glaxo Group Ltd., Greenford | Phenethanolaminderivate |
| US7186864B2 (en) | 2002-05-29 | 2007-03-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| US7074806B2 (en) | 2002-06-06 | 2006-07-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| DK1521733T3 (da) | 2002-07-08 | 2014-10-13 | Pfizer Prod Inc | Modulatorer af glucocorticoid receptoren |
| AU2003251970A1 (en) | 2002-07-18 | 2004-02-09 | Bristol-Myers Squibb Company | Modulators of the glucocorticoid receptor and method |
| GB0217225D0 (en) | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicinal compounds |
| CA2496175A1 (en) | 2002-08-21 | 2004-03-04 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted hihydroquinolines as glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| GB0220730D0 (en) | 2002-09-06 | 2002-10-16 | Glaxo Group Ltd | Medicinal compounds |
| PT1539753E (pt) | 2002-09-16 | 2009-12-10 | Glaxo Group Ltd | Compostos de pirazolo(3,4-b)piridina e sua utilização como inibidores da fosfodiesterase |
| GB0230045D0 (en) | 2002-12-23 | 2003-01-29 | Glaxo Group Ltd | Compounds |
| EP1542996A4 (en) | 2002-09-20 | 2009-11-18 | Merck & Co Inc | OCTAHYDRO-2H-NAPHTOc1,2-F INDOL-4-CARBONSUUREAMIDE DERIVATIVES AS SELECTIVE MODULATORS OF THE GLUCOCORTICOID RECEPTOR |
| GB0224084D0 (en) | 2002-10-16 | 2002-11-27 | Glaxo Group Ltd | Novel compounds |
| JP2006506373A (ja) | 2002-10-22 | 2006-02-23 | グラクソ グループ リミテッド | 医薬アリールエタノールアミン化合物 |
| DK1556342T3 (da) | 2002-10-28 | 2008-07-21 | Glaxo Group Ltd | Phenethanolaminderivat til behandling af respiratoriske sygdomme |
| GB0225030D0 (en) | 2002-10-28 | 2002-12-04 | Glaxo Group Ltd | Medicinal compounds |
| GB0225540D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
| GB0225535D0 (en) | 2002-11-01 | 2002-12-11 | Glaxo Group Ltd | Medicinal compounds |
| TWI328009B (en) | 2003-05-21 | 2010-08-01 | Glaxo Group Ltd | Quinoline derivatives as phosphodiesterase inhibitors |
| GB0316290D0 (en) | 2003-07-11 | 2003-08-13 | Glaxo Group Ltd | Novel compounds |
| SG147436A1 (en) | 2003-10-14 | 2008-11-28 | Glaxo Group Ltd | Muscarinic acetylcholine receptor antagonists |
| DK1699512T3 (da) | 2003-11-03 | 2012-09-17 | Glaxo Group Ltd | Fluiddispenseringsindretning |
| PE20050489A1 (es) | 2003-11-04 | 2005-09-02 | Glaxo Group Ltd | Antagonistas de receptores de acetilcolina muscarinicos |
| WO2005058892A1 (en) | 2003-12-19 | 2005-06-30 | Glaxo Group Limited | Pyrazolo [3,4-b] pyridine compounds, and their use as phosphodiesterase inhibitors |
| GB0405933D0 (en) | 2004-03-16 | 2004-04-21 | Glaxo Group Ltd | Compounds |
| GB0405937D0 (en) | 2004-03-16 | 2004-04-21 | Glaxo Group Ltd | Compounds |
| CA2559629A1 (en) | 2004-03-16 | 2005-09-29 | Glaxo Group Limited | Pyrazolo[3,4-b]pyridine compound, and its use as a pde4 inhibitor |
| AR050902A1 (es) | 2004-04-27 | 2006-12-06 | Glaxo Group Ltd | Compuesto de quinuclidina, composicion farmaceutica que lo comprende y su usopara preparar dicha composicion |
| WO2006000401A1 (en) | 2004-06-28 | 2006-01-05 | Glaxo Group Limited | Substituted oxazines as glucocorticoid receptor modulators |
| WO2006000398A1 (en) | 2004-06-28 | 2006-01-05 | Glaxo Group Limited | 2,3-benzoxazin derivatives as non-steroidal glucocorticoid receptor modulators |
| GB0418045D0 (en) | 2004-08-12 | 2004-09-15 | Glaxo Group Ltd | Compounds |
| WO2006045416A1 (en) | 2004-10-19 | 2006-05-04 | F. Hoffmann-La Roche Ag | Quinoline derivatives |
| WO2006072599A2 (en) | 2005-01-10 | 2006-07-13 | Glaxo Group Limited | Androstane 17-alpha carbonate derivatives for use in the treatment of allergic and inflammatory conditions |
| US20090124588A1 (en) | 2005-01-10 | 2009-05-14 | Glaxo Group Limited | Androstane 17-Alpha-Carbonate for Use in the Treatment of Inflammatory and Allergic Conditions |
| ES2566339T3 (es) * | 2008-06-05 | 2016-04-12 | Glaxo Group Limited | Derivados de 4-carboxamida indazol útiles como inhibidores de PI3-quinasas |
| WO2010102958A1 (en) * | 2009-03-09 | 2010-09-16 | Glaxo Group Limited | 4-oxadiazol-2 -yl- indazoles as inhibitors of p13 kinases |
| PL2899191T3 (pl) * | 2009-04-30 | 2018-01-31 | Glaxo Group Ltd | Indazole podstawione oksazolem jako inhibitory kinazy PI3 |
| ES2602972T3 (es) * | 2010-09-08 | 2017-02-23 | Glaxosmithkline Intellectual Property Development Limited | Derivados de indazol para su uso en el tratamiento de infección por virus de la gripe |
-
2011
- 2011-09-06 SI SI201130595T patent/SI2614058T1/sl unknown
- 2011-09-06 JP JP2013527583A patent/JP5965402B2/ja active Active
- 2011-09-06 EP EP11755311.5A patent/EP2614058B1/en active Active
- 2011-09-06 US US13/821,585 patent/US8735390B2/en active Active
- 2011-09-06 RS RS20150611A patent/RS54286B1/en unknown
- 2011-09-06 HU HUE11755311A patent/HUE026059T2/en unknown
- 2011-09-06 ES ES11755311.5T patent/ES2548036T3/es active Active
- 2011-09-06 WO PCT/EP2011/065419 patent/WO2012032067A1/en active Application Filing
- 2011-09-06 DK DK11755311.5T patent/DK2614058T3/da active
- 2011-09-06 PL PL11755311T patent/PL2614058T3/pl unknown
- 2011-09-06 PT PT117553115T patent/PT2614058E/pt unknown
-
2015
- 2015-09-22 SM SM201500223T patent/SMT201500223B/xx unknown
- 2015-09-28 HR HRP20151017TT patent/HRP20151017T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2614058A1 (en) | 2013-07-17 |
| PL2614058T3 (pl) | 2015-12-31 |
| PT2614058E (pt) | 2015-10-27 |
| RS54286B1 (en) | 2016-02-29 |
| EP2614058B1 (en) | 2015-07-08 |
| JP5965402B2 (ja) | 2016-08-03 |
| SMT201500223B (it) | 2015-10-30 |
| JP2013537175A (ja) | 2013-09-30 |
| HRP20151017T1 (hr) | 2015-10-23 |
| HUE026059T2 (en) | 2016-05-30 |
| US20130165441A1 (en) | 2013-06-27 |
| WO2012032067A1 (en) | 2012-03-15 |
| ES2548036T3 (es) | 2015-10-13 |
| SI2614058T1 (sl) | 2015-10-30 |
| US8735390B2 (en) | 2014-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2614058T3 (da) | Polymorfer og salte af n-[5-[4-(5-{[(2r,6s)-2,6-dimethyl-4-morpholinyl]methyl}-1,3-oxazol-2-yl)-1h-indazol-6-yl]-2-(methyloxy)-3-pyridinyl]methansulfonamid. | |
| US20190328744A1 (en) | Novel compounds | |
| DK2632921T3 (da) | Polymorfer og salte af 6-(1h-indol-4-yl)-4-(5-{[4-(1-methylethyl)-1-piperazinyl]methyl}-1,3-oxazol-2-yl)-1h-indazol som pi3k-inhibitorer til anvendelse i behandling af f.eks. respiratoriske sygdomme | |
| US9353098B2 (en) | Polymorphs and salts |